Eli Lilly

Lilly awards IDRI $4 million in tuberculosis research funding

Tuesday, November 22, 2011 10:55 AM

The Infectious Disease Research Institute (IDRI) has been awarded more than $4 million in additional funding over the next four and a half years by Eli Lilly. The funding will support IDRI’s continued early phase drug discovery research, which focuses on the identification of effective new therapies in the fight against tuberculosis (TB), including multidrug-resistant TB (MDR-TB).

More... »

Kenexa partners with Eli Lilly

Thursday, November 17, 2011 03:08 PM

Kenexa, a global provider of business solutions for human resources, has reported that Eli Lilly will be using Kenexa’s global recruitment process outsourcing (RPO) services in some of the major markets where Lilly conducts business globally. The five year engagement represents Kenexa’s largest global RPO partnership, and also includes Kenexa’s onboarding, recruiting, assessment, and survey solutions and employment branding.  

More... »

Allena Pharmaceuticals secures $15 million in Series A financing

Wednesday, November 16, 2011 03:03 PM

Allena Pharmaceuticals, a company developing and commercializing innovative non-systemic oral protein therapeutics, has secured $15 million in Series A venture capital financing. Bessemer Venture Partners, Frazier Healthcare and Third Rock Ventures led the round. Proceeds from the financing will be used to accelerate the development of Allena's non-systemic protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions.

More... »

Quintiles fills in service offerings with acquisitions

Monday, November 7, 2011 08:00 AM

Quintiles has been on an acquisitions spree. 

More... »

Survey: 80% of big pharma companies restructuring to strategically outsource more trials to CROs

Monday, October 31, 2011 08:00 AM

According to a recent survey from William Blair, about 80% of big pharma companies either are in the process of restructuring or have already completed restructuring plans to strategically outsource more of their trials to CROs.

More... »

Lilly selects Prasco to market generics

Friday, October 28, 2011 11:28 AM

Prasco Laboratories has signed a marketing and distribution agreement with Eli Lilly to market the authorized generic version of ZYPREXA (olanzapine) tablets and ZYPREXA ZYDIS (olanzapine) orally disintegrating tablets, in the U.S.

More... »

Quintiles to acquire Advion BioServices

Wednesday, October 26, 2011 12:01 PM

Quintiles has agreed to buy Advion BioServices, a 19-year-old bioanalytical lab that recently penned a strategic partnership with Eli Lilly.

More... »

Pearl IRB expands into compliance and consulting

Monday, October 17, 2011 08:00 AM

Indianapolis-based Pearl IRB is expanding. The commercial institutional review board, launched just last year, is now adding a regulatory and compliance division, as well as a consulting division that will focus on helping life sciences startups.

More... »

Oncobiologics names Canute to board of directors

Wednesday, October 12, 2011 11:31 AM

Oncobiologics has named Scott Canute to its board of directors.

More... »

Drug sponsors join research partnership to accelerate drug discovery

Thursday, September 29, 2011 01:21 PM

In a bid to save both time and money, some of the industry's biggest names are experimenting with new ways to pool early-stage research, effectively taking a leaf out of the "open-source" manual that gave the world Linux software, according to Reuters.

More... »